In stock COA
NOVALYTE
LABS
LABS
NOVALYTELABS
Cagrilintide10mg · RESEARCH USE ONLY
Cagrilintide10mg · RESEARCH USE ONLY
Low stock COA DOCUMENT SLOT
Metabolic ResearchCagrilintide
Long-acting amylin receptor agonist studied for appetite regulation and metabolic signalling in research models.
Research catalogueLaboratory-use positioning
Batch documentationBatch certificate supplied with order
Order trackingFrom payment to dispatch
Product information
CompoundCagrilintide
Presentation10mg vial
CategoryMetabolic Research
AvailabilityLow stock
Batch COACertificate supplied with order
€55.90
For research use only. Not for human consumption, diagnostic, therapeutic or veterinary use.
Overview
Cagrilintide (NN9838) is a long-acting acylated analog of human amylin (islet amyloid polypeptide, IAPP) developed by Novo Nordisk. Amylin is a 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells after meals. Native amylin has a very short half-life (~15 minutes), whereas cagrilintide's acylation with a C18 fatty di-acid enables albumin binding and extends its half-life to support once-weekly research dosing protocols. It is being studied both alone and in combination with semaglutide (CagriSema) in multiple clinical trials.
Mechanism of Action
Cagrilintide binds to amylin receptors (AMY1, AMY2, AMY3 — heterodimers of the calcitonin receptor with RAMPs 1-3) in the area postrema and hypothalamus. Activation of these receptors promotes satiety signalling, delays gastric emptying, and suppresses postprandial glucagon secretion. Unlike GLP-1 agonists, amylin receptor activation engages distinct neuronal pathways including histaminergic and dopaminergic circuits in the lateral dorsal tegmental area. The complementary mechanisms explain the additive effects observed when combined with GLP-1 receptor agonists.
Research Applications
- Amylin receptor signalling and pharmacology research
- Appetite regulation and satiety pathway studies
- Pancreatic beta cell co-secretion biology
- Combination metabolic agonist research (CagriSema)
- Glucagon suppression and gastric motility studies